Atai Beckley ATAI Stock
Atai Beckley Price Chart
Atai Beckley ATAI Financial and Trading Overview
| Atai Beckley stock price | 4.11 USD |
| Previous Close | 1.78 USD |
| Open | 1.76 USD |
| Bid | 0 USD x 3100 |
| Ask | 0 USD x 3100 |
| Day's Range | 1.74 - 1.8 USD |
| 52 Week Range | 1.14 - 4.96 USD |
| Volume | 670.53K USD |
| Avg. Volume | 1.04M USD |
| Market Cap | 297.16M USD |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.83 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 13.15 USD |
ATAI Valuation Measures
| Enterprise Value | 68.44M USD |
| Trailing P/E | N/A |
| Forward P/E | -1.9888889 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 1100.5847 |
| Price/Book (mrq) | 1.2543797 |
| Enterprise Value/Revenue | 253.473 |
| Enterprise Value/EBITDA | -0.486 |
Trading Information
Atai Beckley Stock Price History
| Beta (5Y Monthly) | N/A |
| 52-Week Change | -44.92% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 4.96 USD |
| 52 Week Low | 1.14 USD |
| 50-Day Moving Average | 1.88 USD |
| 200-Day Moving Average | 2.41 USD |
ATAI Share Statistics
| Avg. Volume (3 month) | 1.04M USD |
| Avg. Daily Volume (10-Days) | 538.97K USD |
| Shares Outstanding | 166.01M |
| Float | 133.3M |
| Short Ratio | 7.33 |
| % Held by Insiders | 9.26% |
| % Held by Institutions | 31.44% |
| Shares Short | 4.97M |
| Short % of Float | 3.91% |
| Short % of Shares Outstanding | 3.00% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -52222.97% |
| Gross Margin | 100.00% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -26.52% |
| Return on Equity (ttm) | -51.83% |
Income Statement
| Revenue (ttm) | 270K USD |
| Revenue Per Share (ttm) | 0.002 USD |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | 233K USD |
| EBITDA | -140828992 USD |
| Net Income Avi to Common (ttm) | -148651008 USD |
| Diluted EPS (ttm) | -0.96 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 249.88M USD |
| Total Cash Per Share (mrq) | 1.51 USD |
| Total Debt (mrq) | 19.01M USD |
| Total Debt/Equity (mrq) | 7.9 USD |
| Current Ratio (mrq) | 13.428 |
| Book Value Per Share (mrq) | 1.427 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -101592000 USD |
| Levered Free Cash Flow (ttm) | -55344000 USD |
Profile of Atai Beckley
| Country | United States |
| State | N/A |
| City | Berlin |
| Address | Wallstrasse 16 |
| ZIP | 10179 |
| Phone | 49 89 2153 9035 |
| Website | https://www.atai.life |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 133 |
ATAI Life Sciences N.V., a clinical-stage biopharmaceutical company, engages in acquiring, incubating, and developing various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its principal clinical programs include RL-007, a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; GRX-917, a deuterated etifoxine for anxiety disorders; VLS-01 a N,N-Dimethyltryptamine for treatment resistant depression (TRD); DMX-1002, an oral formulation of ibogaine, a cholinergic, glutamatergic and monoaminergic receptor modulator that is a naturally occurring psychedelic product isolated from a West African shrub for the treatment of opioid use disorders (OUD); and EMP-01, an oral formulation of an MDMA derivative being developed for the treatment of post-traumatic stress disorder. The company's other clinical programs comprise PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; and KUR-101, a formulation of deuterated mitragynine for the treatment of OUD. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.
Q&A For Atai Beckley Stock
What is a current ATAI stock price?
Atai Beckley ATAI stock price today per share is 4.11 USD.
How to purchase Atai Beckley stock?
You can buy ATAI shares on the Tech Market Middle exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Atai Beckley?
The stock symbol or ticker of Atai Beckley is ATAI.
Which industry does the Atai Beckley company belong to?
The Atai Beckley industry is Biotechnology.
How many shares does Atai Beckley have in circulation?
The max supply of Atai Beckley shares is 363.21M.
What is Atai Beckley Price to Earnings Ratio (PE Ratio)?
Atai Beckley PE Ratio is now.
What was Atai Beckley earnings per share over the trailing 12 months (TTM)?
Atai Beckley EPS is -0.83 USD over the trailing 12 months.
Which sector does the Atai Beckley company belong to?
The Atai Beckley sector is Healthcare.
Atai Beckley ATAI included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| US Tech Composite IXIC | 23600.59 USD — |
-0.05
|
2.5B USD — | 23567.86 USD — | 23665.15 USD — | — - | 2.5B USD — |
| US Tech Global Market Composite NQGM | 2323.7 USD — |
-0.96
|
— — | 2316.74 USD — | 2339.59 USD — | — - | — — |
| US Tech Biotechnology NBI | 5797.13 USD — |
-0.8
|
— — | 5792.54 USD — | 5835.34 USD — | — - | — — |
| US Tech Health Care IXHC | 1203.99 USD — |
-0.67
|
— — | 1203.88 USD — | 1210.54 USD — | — - | — — |
| US Tech Composite Total Return XCMP | 29034.87 USD — |
<0.01
|
— — | 28980.01 USD — | 29099.65 USD — | — - | — — |
| Stlmt ID US Tech Biotechnology NBX | 3995.9 USD — |
-4.37
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
- {{ link.label }} {{link}}